This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Siu, I-M. Articles by Riggins, G. J. Search for Related Content PubMed PubMed Citation Articles by Siu, I-M. Articles by Riggins, G. J.

c-Myc Promoter Activation in Medulloblastoma¹

Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710

%The c-myc oncogene is commonly activated in medulloblastoma. Genomic amplification is a well-documented cause of c-myc activation but does not account for all cases of c-myc activation. In this study, we sought other means by which c-myc is overexpressed in medulloblastoma. Twelve medulloblastoma or PNET cell lines were screened for c-myc genomic amplification, mRNA levels, and protein levels. Two medulloblastoma lines, D283 Med and D721 Med, were identified that expressed c-myc mRNA and protein at high levels without genomic amplification. The c-myc gene’s regulatory sequences were normal in those cell lines. However, specific regions of the promoter, independent of the ß-catenin binding sites, were responsible for activation as revealed by promoter assays and site-directed mutagenesis. Transcriptional activation by a ß-catenin-independent pathway is therefore a likely mechanism for c-myc overexpression in a subset of medulloblastomas.

This article has been cited by other articles:

				E. Salsano, L. Croci, E. Maderna, L. Lupo, B. Pollo, M. T. Giordana, G. G. Consalez, and G. Finocchiaro Expression of the neurogenic basic helix-loop-helix transcription factor NEUROG1 identifies a subgroup of medulloblastomas not expressing ATOH1 Neuro-oncol, July 1, 2007; 9(3): 298 - 307. [Abstract] [Full Text] [PDF]

				S. Rutkowski, A. von Bueren, K. von Hoff, W. Hartmann, T. Shalaby, F. Deinlein, M. Warmuth-Metz, N. Soerensen, A. Emser, U. Bode, et al. Prognostic Relevance of Clinical and Biological Risk Factors in Childhood Medulloblastoma: Results of Patients Treated in the Prospective Multicenter Trial HIT'91 Clin. Cancer Res., May 1, 2007; 13(9): 2651 - 2657. [Abstract] [Full Text] [PDF]

				D. Stearns, A. Chaudhry, T. W. Abel, P. C. Burger, C. V. Dang, and C. G. Eberhart c-Myc Overexpression Causes Anaplasia in Medulloblastoma Cancer Res., January 15, 2006; 66(2): 673 - 681. [Abstract] [Full Text] [PDF]

				A. Huang, C. S.W. Ho, R. Ponzielli, D. Barsyte-Lovejoy, E. Bouffet, D. Picard, C. E. Hawkins, and L. Z. Penn Identification of a Novel c-Myc Protein Interactor, JPO2, with Transforming Activity in Medulloblastoma Cells Cancer Res., July 1, 2005; 65(13): 5607 - 5619. [Abstract] [Full Text] [PDF]

				K. Boon, C. G. Eberhart, and G. J. Riggins Genomic Amplification of Orthodenticle Homologue 2 in Medulloblastomas Cancer Res., February 1, 2005; 65(3): 703 - 707. [Abstract] [Full Text] [PDF]